Mathematics
Clinical Trials
7%
Genotype
26%
Infection
21%
Inhibitor
65%
Mutation
52%
Protease
84%
Resistance
55%
Sequencing
8%
Standards
4%
Therapy
59%
Agriculture & Biology
chronic hepatitis C
100%
clinical trials
6%
demographic statistics
5%
Denmark
56%
genotype
11%
hepatitis B
9%
hepatitis C
11%
infection
10%
interferons
7%
mutation
35%
proteinase inhibitors
55%
proteinases
9%
relapse
8%
reverse transcriptase polymerase chain reaction
5%
sequence diversity
6%
therapeutics
35%
Earth & Environmental Sciences
analysis
1%
genotype
24%
hepatitis
72%
infection
20%
inhibitor
48%
mutation
52%
rate
2%
therapy
55%
trial
6%
Medicine & Life Sciences
Antiviral Agents
3%
Chronic Hepatitis C
54%
Clinical Trials
2%
Databases
2%
Demography
2%
Denmark
55%
Genotype
9%
Hepatitis B
4%
Hepatitis C
4%
Infections
6%
Interferons
4%
Mutation
29%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
6%
Peptide Hydrolases
7%
Polymerase Chain Reaction
2%
Protease Inhibitors
54%
Recurrence
2%
Ribavirin
4%
Standard of Care
4%
telaprevir
6%
Therapeutics
8%
Treatment Failure
4%
Engineering & Materials Science
Interferons
18%
Peptide Hydrolases
79%